Caris Life Sciences stock falls after hours despite Q3 beat, BTIG maintains buy
Caris Life Sciences (NASDAQ:CAI) shares fell 13% after hours despite Q3 revenue beat of $275.4M (up 27% YoY) and raised guidance. BTIG maintains a Buy rating and $38 target, citing strong growth but noting concerns over Q4 2026 guidance. The company plans to launch a new test in December. Adjusted earnings missed at $0.05 per share vs. $0.16 expected.
How this was made
The 30-second read
Why it matters
The earnings miss and cautious Q4 guidance triggered a sharp after‑hours sell‑off, but analyst support remains, creating a potential short‑term entry point.
Market read
The report provides fresh earnings data and guidance for CAI, influencing short‑term price action and offering a potential trade signal.
What to watch
Strong revenue growth and new test launches could support longer‑term upside despite short‑term miss.
Background
Caris Life Sciences is a precision oncology diagnostics company that recently launched new sequencing‑based tests.
Ticker impact
Caris Life Sciences reported Q3 earnings that beat revenue expectations but missed EPS, prompting a 13% after‑hours price drop despite a BTIG buy rating.
downward pressure as the market prices in the earnings miss and cautious guidance
The stock fell 13% in after‑hours despite a beat, indicating traders view the miss and guidance as a near‑term downside catalyst.
Market effects
Precision oncology diagnostics may face heightened scrutiny on guidance guidance, affecting peers.
US biotech sector may see modest pullback as earnings miss spreads.
Limited; impact confined to US biotech and related investors.
Counterpoint
BTIG maintains a buy rating and a $38 target, suggesting the dip may be an overreaction and a buying opportunity.
Key entities
- analystBTIG
Maintained buy rating and $38 price target.
- analystTD Cowen
Raised price target to $38.


